Last reviewed · How we verify
Female infertility — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Clomid | clomifene | Sanofi | Estrogen Agonist/Antagonist | 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | 1967-01-01 | |
| Clomid | Clomid | rana alaaeldin aly ibrahim nasr | 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6, Adenosine receptor A3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Sanofi · 1 drug in Female infertility
- rana alaaeldin aly ibrahim nasr · 1 drug in Female infertility
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Female infertility:
- Female infertility treatment updates — RSS
- Female infertility treatment updates — Atom
- Female infertility treatment updates — JSON
Cite this brief
Drug Landscape (2026). Female infertility — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/female-infertility. Accessed 2026-06-10.
Related
- Female infertility full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing